Related Experiment Videos
Different tau epitopes define Abeta42-mediated tau insolubility
1Division of Psychiatry Research, University of Zürich, August Forel Street 1, 8008 Zürich, Switzerland.
Biochemical and Biophysical Research Communications
|October 18, 2005
Summary
Alzheimer's disease research shows beta-amyloid (Abeta(42)) impacts tau protein solubility. This effect depends on multiple tau phosphorylation sites, not just S422, influencing neurofibrillary tangle formation.
Area of Science:
- Neuroscience
- Cell Biology
- Biochemistry
Background:
- Alzheimer's disease (AD) pathology involves beta-amyloid (Abeta(42)) plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein.
- Previous studies indicated pathological interactions between Abeta(42) and tau in neuroblastoma cells.
- Mutating the S422 phospho-epitope of tau prevented Abeta(42)-induced tau aggregation and solubility changes.
Purpose of the Study:
- To investigate the role of tau phosphorylation and cleavage sites in tau aggregation.
- To further elucidate the mechanisms underlying Abeta(42)-mediated tau pathology.
Main Methods:
- Utilized human SH-SY5Y neuroblastoma cells overexpressing wild-type and mutant forms of human tau.
- Exposed cells to pre-aggregated forms of Abeta(42).
- Analyzed tau solubility and aggregation patterns in response to various tau mutants.
Main Results:
- Exposure to Abeta(42) induced the formation of AD-like tau filaments and decreased tau solubility.
- The Abeta(42)-mediated decrease in tau solubility is dependent on the interplay of multiple tau phospho-epitopes.
- This effect is not solely dependent on the phosphorylation of the S422 epitope.
Conclusions:
- Tau phosphorylation and cleavage sites play a complex role in Abeta(42)-induced tau pathology.
- Understanding the interplay of tau phospho-epitopes is crucial for comprehending Alzheimer's disease pathogenesis.
- Targeting specific tau phosphorylation sites may offer therapeutic strategies for AD.